返回 
加入收藏
阿立哌唑/利培酮联合多奈哌齐治疗阿尔茨海默病的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 阿立哌唑/利培酮联合多奈哌齐治疗阿尔茨海默病的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察阿立哌唑/利培酮联合多奈哌齐治疗阿尔茨海默病的疗效及安全性。方法：选取阿尔茨海默病患者46例，按随机数字表法分为对照组（24例）和试验组（22例）。两组患者均给予多奈哌齐5 mg，qd，基础治疗，在此基础上对照组患者给予利培酮初始剂量1 mg，并根据病情逐渐增加至2～4 mg，qd；试验组患者给予阿立哌唑10 mg，qd。两组患者均治疗8周。采用阿尔茨海默病病理行为评定量表（BEHAV-AD）及社会功能评定量表（PSP）对两组患者治疗前及治疗后2、4、6、8周的各项指标进行评分，并比较两组患者副反应量表（TESS）评分。结果：治疗后，两组患者BEHAV-AD评分均显著下降，试验组下降更为显著，差异有统计学意义（P＜0.05）；治疗后，试验组患者行为紊乱、攻击行为、谵妄、抑郁、焦虑评分显著低于对照组，差异有统计学意义（P＜0.05），偏执、幻觉评分比较，差异无统计学意义（P＞0.05）；治疗后两组患者PSP评分均显著升高，且试验组升高更为显著，差异有统计学意义（P＜0.05）。试验组患者毒副反应评分显著低于对照组，差异有统计学意义（P＜0.05）。 结论：阿立哌唑/利培酮联用多奈哌齐对阿尔茨海默病均有效，而阿立哌唑效更为确切，且安全性较好。 |
| ABSTRACT： | OBJECTIVE： To observe therapeutic efficacy and safety of aripirazle or risperidone combined with donepezil in the treatment of Alzheimer disease. METHODS： 46 patients with alzheimer disease were randomly divided into control group （n＝24） and experiment group（n＝22）. Both groups received routine treatment， donepezil 5 mg， qd； control group was additionally given risperidone 1 mg， increasing to 2-4 mg， qd， according to disease condition； experiment group was additionally given aripirazle 10 mg， qd. Both groups were given 8 weeks of treatment. BEHAV-AD score and PSP score of each indicators in 2 groups were recorded before treatment， 2， 4， 6 and 8 weeks after treatment， and TESS score were compared between 2 groups. RESULTS： After treatment， BEHAV-AD score of 2 groups decreased significantly， especially in experiment group， with statistical significance （P＜0.05）. After treatment， the score for aggressive behavior， conduct disorder， depress and anxiety in experiment group were much lower than that of control group， with statistical significance （P＜0.05）； there was no statistical significance in crankiness， hallucination and deliration score （P＞0.05）. After treatment，PSP score of 2 groups elevated markedty， the test group increased more significantly，with statistical significance（P＜0.05） ADR score of experiment group was significantly lower than that of control group， with statistical significance （P＜0.05）. CONCLUSIONS： Both aripirazle or risperidone combined with donepezil is effective for Alzheimer disease， and aripirazle combined with donepezil shows more definite efficacy and better safety. |
| 期刊： | 2016年第27卷第2期 |
| 作者： | 雷四英 |
| AUTHORS： | LEI Siying |
| 关键字： | 阿立哌唑；利培酮；多奈哌齐；阿尔茨海默病；疗效；安全性 |
| KEYWORDS： | Aripirazle； Risperidone； Donepezil； Alzheimer disease； Efficacy； Safety |
| 阅读数： | 558 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
